Members of BSPED who wish to undertake a national audit in a topic relating to Endocrinology or Diabetes should send a brief proposal (one side of A4 and clearly stating what assistance is required from BSPED) to the Audit/Peer Review Officer Dr Indi Banerjee at Thereafter the proposal will be discussed for approval by the BSPED Clinical Committee. A report of a completed audit should be submitted to the Clinical Committee.

The responsibility for audit studies endorsed and supported by BSPED moved to become part of the remit of the BSPED Clinical Committee in 2011.

Audits in progress

Name of Audit Lead Investigator
Growth Hormone Audit Dr Indi Banerjee
Transitional Care in Endocrinology Dr Helena Gleeson


Growth Hormone Audit

Recombinant human growth hormone (GH) or Somatropin treatment in children and young people is licensed in the UK [NICE HTA 188, 2010] for the following diagnosis:

  • Growth Hormone Deficiency (GHD)
  • Turner Syndrome (TS)
  • Chronic Renal Insufficiency (CRI)
  • Prader-Willi Syndrome (PWS)
  • born Small for Gestational Age (SGA) with subsequent growth failure at 4 years of age or later
  • Short Stature Homeobox-containing gene (SHOX) deficiency

It is usually prescribed by, or in collaboration with, a paediatric endocrinologist, most of whom are members of the British Society for Paediatric Endocrinology and Diabetes (BSPED).

The BSPED National Growth Hormone (GH) audit was initiated in January 2013 to establish an ongoing audit, including linked anonymised data, of all children and adolescents newly-prescribed GH treatment in the UK. The aim of this audit is to:

  1. allow monitoring of ongoing trends in prescribing practice
  2. facilitate future long-term follow-up of individuals receiving GH therapy during the childhood/adolescent years

This audit also fulfils a recommendation from NICE. Every UK clinician (including non-BSPED members) who initiates GH therapy in children and/or adolescents in the UK is invited to submit data. Every paediatric patient aged ≤ 16.0 years newly starting GH treatment in the UK is eligible to be included. Linked anonymised data is being collected and collated quarterly by the Office for Rare Conditions in Glasgow, on behalf of the BSPED Clinical Committee. A report can be found below. This includes information about the total number of patients started on GH for defined periods, and also by gender, region and indications for the treatment.

The BSPED Growth Hormone Audit report is available to BSPED members only.